Croyle Recipient of Prestigious Hill Prize

A woman smiling.
February 5, 2024
Professor of Molecular Pharmaceutics and Drug Delivery and Glaxo Wellcome Professor Maria A. Croyle, Ph.D. is a recipient of the prestigious and highly competitive Hill Prize. The prizes, funded by Lyda Hill Philanthropies, accelerate high-risk, high-reward research ideas with significant potential for real-world impact.

Croyle Wins Best Paper in 2022 Co-op Research Excellence Awards

A woman smiling.
November 4, 2022
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle, Ph.D. earned this year's Best Paper Award from the University Co-op Research Excellence Awards, presented by UT's Office of the Vice President for Research, Scholarship and Creative Endeavors and the University Co-operative Society.

Faculty Earn State Grants for Cancer Research

A person in a lab.
September 21, 2022
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism

A man smiling in a research lab.
September 7, 2021
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Maniruzzaman Lab Earns Grant to Research 3D Printed COVID-19 Treatment

A man holding up a dish in a lab.
May 26, 2021
The UT College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab earned a Texas Global Faculty Research Seed Grant for its work on patient-specific treatment of COVID-19.

Suh and PharmE3D Labs Win Fellowships for 3D Bioprinting Research

A woman smiling in front of a sign that says "Pharmacy."
March 18, 2021
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.